Skip to main content

Table 1 Baseline demographics

From: Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab

 

Eptinezumab 300 mg (N = 128)

Mean (SD) age, years

41.5 (11.33)

Sex, n (%)

  Male

19 (14.8)

  Female

109 (85.2)

Ethnicity, n (%)

  Hispanic or Latino

26 (20.3)

  Not Hispanic or Latino

102 (79.7)

Race, n (%)

  White

122 (95.3)

  Black or African American

4 (3.1)

  Asian

1 (< 1)

  Multiple races

1 (< 1)

  1. SD Standard deviation